{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:21:04Z","timestamp":1787458864260,"version":"build-2736575974"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04342-4","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:21:49Z","timestamp":1774970509000},"page":"3739-3753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies"],"prefix":"10.1007","volume":"28","author":[{"given":"Xiaohong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4240-5378","authenticated-orcid":false,"given":"Ximing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"10","key":"4342_CR1","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1007\/s00261-019-02278-8","volume":"45","author":"AK Hanafy","year":"2020","unstructured":"Hanafy AK, Morani AC, Menias CO, Pickhardt PJ, Shaaban AM, Mujtaba B, et al. Hematologic malignancies of the gastrointestinal luminal tract. Abdom Radiol (NY). 2020;45(10):3007\u201327.","journal-title":"Abdom Radiol (NY)"},{"key":"4342_CR2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"S Swerdlow","year":"2017","unstructured":"Swerdlow S, Campo E, Harris N, Jaffe E. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2017."},{"issue":"12","key":"4342_CR3","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.5858\/arpa.2020-0661-RA","volume":"145","author":"J Alvarez-Lesmes","year":"2021","unstructured":"Alvarez-Lesmes J, Chapman JR, Cassidy D, Zhou Y, Garcia-Buitrago M, Montgomery EA, et al. Gastrointestinal Tract Lymphomas. Arch Pathol Lab Med. 2021;145(12):1585\u201396.","journal-title":"Arch Pathol Lab Med"},{"key":"4342_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107406","volume":"135","author":"Q Lai","year":"2023","unstructured":"Lai Q, Zhao Y, Yan H, Peng H. Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL. Leuk Res. 2023;135:107406.","journal-title":"Leuk Res"},{"issue":"1","key":"4342_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-04537-9","volume":"15","author":"Y Feng","year":"2025","unstructured":"Feng Y, Zheng S, Sun Y, Liu L. Location-specific analysis of clinicopathological characteristics and long-term prognosis of primary gastrointestinal diffuse large B-cell lymphoma. Sci Rep. 2025;15(1):19574 (Published 2025 Jun 4).","journal-title":"Sci Rep"},{"issue":"8","key":"4342_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.17219\/acem\/94068","volume":"28","author":"M Olszewska-Szopa","year":"2019","unstructured":"Olszewska-Szopa M, Wr\u00f3bel T. Gastrointestinal non-Hodgkin lymphomas. Adv Clin Exp Med. 2019;28(8):1119\u201324.","journal-title":"Adv Clin Exp Med"},{"issue":"5","key":"4342_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00428-019-02704-8","volume":"476","author":"S Montes-Moreno","year":"2020","unstructured":"Montes-Moreno S, King RL, Oschlies I, Ponzoni M, Goodlad JR, Dotlic S, et al. Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. Virchows Archiv: Int J Pathol. 2020;476(5):667\u201381.","journal-title":"Virchows Archiv: Int J Pathol"},{"issue":"3","key":"4342_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MOG.0000000000000829","volume":"38","author":"P Oka","year":"2022","unstructured":"Oka P, Sidhu R. Small bowel lymphoma: clinical update and challenges for the gastroenterologist. Curr Opin Gastroenterol. 2022;38(3):270\u20138.","journal-title":"Curr Opin Gastroenterol"},{"key":"4342_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109793","volume":"141","author":"L Zanoni","year":"2021","unstructured":"Zanoni L, Mattana F, Calabr\u00f2 D, Paccagnella A, Broccoli A, Nanni C, et al. Overview and recent advances in PET\/CT imaging in lymphoma and multiple myeloma. Eur J Radiol. 2021;141:109793.","journal-title":"Eur J Radiol"},{"issue":"3","key":"4342_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1053\/j.semnuclmed.2022.11.003","volume":"53","author":"EM Veziroglu","year":"2023","unstructured":"Veziroglu EM, Farhadi F, Hasani N, Nikpanah M, Roschewski M, Summers RM, et al. Role of artificial intelligence in PET\/CT imaging for management of lymphoma. Semin Nucl Med. 2023;53(3):426\u201348.","journal-title":"Semin Nucl Med"},{"issue":"9","key":"4342_CR11","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/annonc\/mdt188","volume":"24","author":"R Vaidya","year":"2013","unstructured":"Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, et al. Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol. 2013;24(9):2439\u201343.","journal-title":"Ann Oncol"},{"issue":"11","key":"4342_CR12","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.4251\/wjgo.v16.i11.4409","volume":"16","author":"XH Liu","year":"2024","unstructured":"Liu XH, Chen G, Cao DD, Liu H, Ke XK, Hu YG, et al. Comparison of clinical features of patients with or without severe gastrointestinal complications in aggressive gastrointestinal lymphomas. World J Gastrointest Oncol. 2024;16(11):4409\u201323.","journal-title":"World J Gastrointest Oncol"},{"key":"4342_CR13","first-page":"1","volume":"8","author":"F Modemann","year":"2023","unstructured":"Modemann F, Ahmadi P, von Kroge PH, Weidemann S, Bokemeyer C, Dierlamm J, et al. The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma a single center analysis. Leuk Lymphoma. 2023;8:1\u201310.","journal-title":"Leuk Lymphoma"},{"key":"4342_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2147\/CMAR.S295671","volume":"13","author":"Y Shen","year":"2021","unstructured":"Shen Y, Ou J, Wang B, Wang L, Xu J, Cen X. Influence of severe gastrointestinal complications in primary gastrointestinal diffuse large B-cell lymphoma. Cancer Manag Res. 2021;13:1041\u201352.","journal-title":"Cancer Manag Res"},{"issue":"9","key":"4342_CR15","doi-asserted-by":"publisher","first-page":"768.e1","DOI":"10.1016\/j.jtct.2021.05.018","volume":"27","author":"A Cortes-Bullich","year":"2021","unstructured":"Cortes-Bullich A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, et al. Outcomes of CD19 chimeric antigen receptor T Cell therapy in patients with gastrointestinal tract involvement of large B Cell lymphoma. Transplant Cell Ther. 2021;27(9):768.e1-768.e6.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"4342_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12185-019-02687-x","volume":"110","author":"AM Maeshima","year":"2019","unstructured":"Maeshima AM, Taniguchi H, Ito Y, Hatta S, Suzuki T, Yuda S, et al. Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients. Int J Hematol. 2019;110(3):340\u20136.","journal-title":"Int J Hematol"},{"issue":"14","key":"4342_CR17","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1200\/JCO.2003.06.026","volume":"21","author":"S Daum","year":"2003","unstructured":"Daum S, Ullrich R, Heise W, Dederke B, Foss HD, Stein H, et al. Intestinal non-Hodgkin\u2019s lymphoma: A multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin\u2019s Lymphoma. J Clin Oncol. 2003;21(14):2740\u20136.","journal-title":"J Clin Oncol"},{"issue":"18","key":"4342_CR18","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1200\/JCO.2001.19.18.3861","volume":"19","author":"P Koch","year":"2001","unstructured":"Koch P, Del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin\u2019s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01\/92. J Clin Oncol. 2001;19(18):3861\u201373.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4342_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2478\/raon-2019-0045","volume":"53","author":"C Rajasooriyar","year":"2019","unstructured":"Rajasooriyar C, Tey J, Wong LC, Poon M, Nandini R, Tham I, et al. A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes. Radiol Oncol. 2019;53(4):473\u20139.","journal-title":"Radiol Oncol"},{"issue":"11","key":"4342_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group. Lancet Oncol. 2011;12(11):1013\u201322.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4342_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Ho AD, Cavallin\u2010Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good\u2010prognosis diffuse large\u2010B\u2010cell lymphoma treated with CHOP\u2010like chemotherapy with or without rituximab: an exploratory analysis of the MabThera international trial group (MInT) study. Lancet Oncol. 2008;9(5):435-444.6.","journal-title":"Lancet Oncol"},{"key":"4342_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000350051","volume":"87","author":"S Nakamura","year":"2013","unstructured":"Nakamura S, Matsumoto T. Gastrointestinal lymphoma: Recent advances in diagnosis and treatment. Digestion. 2013;87:182\u20138.","journal-title":"Digestion"},{"issue":"5","key":"4342_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12052054","volume":"12","author":"K Yoshida","year":"2023","unstructured":"Yoshida K, Iwashita T, Mita N, Iwasa Y, Uemura S, Shimizu M. Efficacy of contrast-enhanced endoscopic ultrasonography for the differentiation of Non-Hodgkin\u2019s lymphoma: A single-center retrospective cohort study. J Clin Med. 2023;12(5):2054.","journal-title":"J Clin Med"},{"issue":"5","key":"4342_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2559.2007.02855.x","volume":"51","author":"J Connor","year":"2007","unstructured":"Connor J, Ashton-Key M. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study. Histopathology. 2007;51(5):697\u2013703.","journal-title":"Histopathology"},{"issue":"1","key":"4342_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00000478-199801000-00003","volume":"22","author":"ED Hsi","year":"1998","unstructured":"Hsi ED, Eisbruch A, Greenson JK, Singleton TP, Ross CW, Schnitzer B. Classification of primary gastric lymphomas according to histologic features. Am J Surg Pathol. 1998;22(1):17\u201327.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"4342_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/PAI.0000000000000843","volume":"28","author":"I Cho","year":"2020","unstructured":"Cho I, Yoon N, Hyeon J, Sim J, Yoo HY, Kim SJ, et al. Comparison of the lymph2Cx assay and Han\u2019s algorithm in determining the cell-of-origin of diffuse large B-cell lymphomas, not otherwise specified. Appl Immunohistochem Mol Morphol. 2020;28(10):731\u201340.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"4342_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ijlh.14158","volume":"45","author":"D Peng","year":"2023","unstructured":"Peng D, Kodituwakku A, Le S, Smith SABC, Qiu MR, Earls P, et al. Factors determining whether diffuse large B-cell lymphoma samples are detected by flow cytometry. Int J Lab Hematol. 2023;45(6):927\u201334.","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"4342_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/jclinpath-2019-206199","volume":"73","author":"Z Ma","year":"2020","unstructured":"Ma Z, Niu J, Cao Y, Pang X, Cui W, Zhang W, et al. Clinical significance of \u201cdouble-hit\u201d and \u201cdouble-expression\u201d lymphomas. J Clin Pathol. 2020;73(3):126\u201338.","journal-title":"J Clin Pathol"},{"issue":"1","key":"4342_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjh.15778","volume":"185","author":"C Lees","year":"2019","unstructured":"Lees C, Keane C, Gandhi MK, Gunawardana J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019;185(1):25\u201341.","journal-title":"Br J Haematol"},{"issue":"4","key":"4342_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/MOH.0000000000000155","volume":"22","author":"A Mottok","year":"2015","unstructured":"Mottok A, Steidl C. Genomic alterations underlying immune privilege in malignant lymphomas. Curr Opin Hematol. 2015;22(4):343\u201354 (30).","journal-title":"Curr Opin Hematol"},{"issue":"26","key":"4342_CR31","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848\u201356.","journal-title":"J Clin Oncol"},{"issue":"17","key":"4342_CR32","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","volume":"15","author":"WW Choi","year":"2009","unstructured":"Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494\u2013502.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4342_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bjh.17246","volume":"192","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Glover P, Taylor J, Sha C, Care MA, Tooze R, et al. Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. Br J Haematol. 2021;192(3):599\u2013604.","journal-title":"Br J Haematol"},{"issue":"1","key":"4342_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/cas.16377","volume":"116","author":"YF Wu","year":"2025","unstructured":"Wu YF, Yuan QH, Shen HR, Du KX, Shang CY, Li Y, et al. The prognostic significance of MYC\/BCL2 double expression in DLBCL in the genetic classification era. Cancer Sci. 2025;116(1):257\u201370.","journal-title":"Cancer Sci"},{"issue":"10","key":"4342_CR35","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.7150\/jca.15395","volume":"7","author":"M He","year":"2016","unstructured":"He M, Chen K, Li S, Zhang S, Zheng J, Hu X, et al. Clinical Significance of \u201cDouble-hit\u201d and \u201cDouble-protein\u201d expression in Primary Gastric B-cell Lymphomas. J Cancer. 2016;7(10):1215\u201325.","journal-title":"J Cancer"},{"issue":"1","key":"4342_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41408-025-01250-8","volume":"15","author":"R Karmali","year":"2025","unstructured":"Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, et al. Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood Cancer J. 2025;15(1):43.","journal-title":"Blood Cancer J"},{"issue":"12","key":"4342_CR37","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.2023021002","volume":"143","author":"L Cerchietti","year":"2024","unstructured":"Cerchietti L. Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large b-cell lymphoma. Blood. 2024;143(12):1101\u201311.","journal-title":"Blood"},{"issue":"1","key":"4342_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1073274818778256","volume":"25","author":"LM Jua\u00b4rez-Salcedo","year":"2018","unstructured":"Jua\u00b4rez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment. Cancer Control. 2018;25(1):1073274818778256.","journal-title":"Cancer Control"},{"issue":"3","key":"4342_CR39","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/bjh.15953","volume":"186","author":"B Kiesewetter","year":"2019","unstructured":"Kiesewetter B, Lamm W, Dolak W, Lukas J, Mayerhoefer ME, Weber M, et al. Transformed mucosa-associated lymphoid tissue lymphomas: a single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019;186(3):448\u201359.","journal-title":"Br J Haematol"},{"issue":"6","key":"4342_CR40","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bjh.14153","volume":"174","author":"AM Maeshima","year":"2016","unstructured":"Maeshima AM, Taniguchi H, Toyoda K, Yamauchi N, Makita S, Fukuhara S, et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016;174(6):923\u201331.","journal-title":"Br J Haematol"},{"issue":"1","key":"4342_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/his.14289","volume":"78","author":"PG Foukas","year":"2021","unstructured":"Foukas PG, Bisig B, de Leval L. Recent advances upper gastrointestinal lymphomas: molecular updates and diagnostic implications. Histopathology. 2021;78(1):187\u2013214.","journal-title":"Histopathology"},{"key":"4342_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6067-5","volume":"19","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Xiao Y, Zhou R, Liao Y, Zhou J, Ma X. Prognostic significance of Helicobacter pylori-infection in gastric diffuse large b-cell lymphoma. BMC Cancer. 2019;19:842.","journal-title":"BMC Cancer"},{"issue":"1","key":"4342_CR43","doi-asserted-by":"publisher","first-page":"2193423","DOI":"10.1080\/07853890.2023.2193423","volume":"55","author":"Y Feng","year":"2023","unstructured":"Feng Y, Duan TJ, Huang Q, Li ZY, Liu YP, Luo MS, et al. The clinicopathological characteristics of gastric cancer and precancerous conditions in gastric DLBCL and MALT lymphoma patients: a multi-center retrospective study. Ann Med. 2023;55(1):2193423.","journal-title":"Ann Med"},{"key":"4342_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00535-019-01616-3","volume":"55","author":"E Ishikawa","year":"2020","unstructured":"Ishikawa E, Nakamura M, Shimada K, Tanaka T, Satou A, Kohno K, et al. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. J Gastroenterol. 2020;55:39\u201350.","journal-title":"J Gastroenterol"},{"key":"4342_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12253-012-9585-x","volume":"19","author":"Z Zizhen","year":"2013","unstructured":"Zizhen Z, Hui C, Yanying S, Danping S, Jiahua L, Chao H, et al. Correlation between immunophenotype classification and clinicopathological features in Chinese patients with primary gastric diffuse large b-cell lymphoma. Pathol Oncol Res. 2013;19:317\u201322.","journal-title":"Pathol Oncol Res"},{"issue":"Suppl. 6","key":"4342_CR46","doi-asserted-by":"publisher","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","volume":"24","author":"E Zucca","year":"2013","unstructured":"Zucca E, Copie-Bergman C, Ricardi U, Ricardi U, Thieblemont C, Raderer M, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi144\u20138.","journal-title":"Ann Oncol."},{"key":"4342_CR47","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/apt.15409","volume":"50","author":"T Matysiak-Budnik","year":"2019","unstructured":"Matysiak-Budnik T, Jamet P, Ruskone-Fourmestraux A, de Mascarel A, Velten M, Maynadi\u00e9 M, et al. Gastric MALT lymphoma in a population-based study in France: clinical features, treatments and survival. Aliment Pharmacol Ther. 2019;50:654\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"4342_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102656","volume":"2015","author":"K Troppan","year":"2015","unstructured":"Troppan K, Wenzl K, Neumeister P, Deutsch A. Molecular pathogenesis of MALT lymphoma. Gastroenterol Res Pract. 2015;2015:102656.","journal-title":"Gastroenterol Res Pract"},{"key":"4342_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00428-011-1153-3","volume":"459","author":"SY Choi","year":"2011","unstructured":"Choi SY, Kim SJ, Kim WS, Kim K, Ko YH. Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis. Virchows Arch. 2011;459:495\u2013502.","journal-title":"Virchows Arch"},{"key":"4342_CR50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/00365520510024205","volume":"41","author":"N Yoshida","year":"2006","unstructured":"Yoshida N, Nomura K, Wakabayashi N, Konishi H, Nishida K, Taki T, et al. Cytogenetic and clinicopathological characterization by fluorescence in situ hybridization on paraffin-embedded tissue sections of twentysix cases with malignant lymphoma of small intestine. Scand J Gastroenterol. 2006;41:212\u201322.","journal-title":"Scand J Gastroenterol"},{"key":"4342_CR51","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"4342_CR52","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1080\/10428190802238552","volume":"49","author":"KA Mitchell","year":"2008","unstructured":"Mitchell KA, Finn WG, Owens SR. Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas. Leuk Lymphoma. 2008;49:1717\u201323.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"4342_CR53","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/sj.leu.2404244","volume":"20","author":"E Haralambieva","year":"2006","unstructured":"Haralambieva E, Adam P, Ventura R, Katzenberger T, Kalla J, H\u00f6ller S, et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia. 2006;20(7):1300\u20133.","journal-title":"Leukemia"},{"issue":"16","key":"4342_CR54","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2006.05.6150","volume":"24","author":"X Sagaert","year":"2006","unstructured":"Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(16):2490\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4342_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","volume":"97","author":"T Fischer","year":"2018","unstructured":"Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S. Transformed follicular lymphoma. Ann Hematol. 2018;97(1):17\u201329.","journal-title":"Ann Hematol"},{"issue":"4","key":"4342_CR56","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","volume":"125","author":"C Correia","year":"2015","unstructured":"Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125(4):658\u201367.","journal-title":"Blood"},{"issue":"1","key":"4342_CR57","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130\u201340.","journal-title":"Cell Rep"},{"issue":"9759","key":"4342_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2001","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomis controlled trial. Lancet. 2001;377(9759):42\u201351.","journal-title":"Lancet"},{"issue":"3","key":"4342_CR59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1182\/blood-2017-03-691345","volume":"130","author":"R Kridel","year":"2017","unstructured":"Kridel R, Sehn LH, Gascoyne RD. Can histologic transformation of follicular lymphoma be predicted and prevented? Blood. 2017;130(3):258\u201366.","journal-title":"Blood"},{"issue":"9","key":"4342_CR60","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","volume":"121","author":"MR Green","year":"2013","unstructured":"Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, et al. Hierarchy in somatic mutations arising during genomic Ann Hematol evolution and progression of follicular lymphoma. Blood. 2013;121(9):1604\u201311.","journal-title":"Blood"},{"issue":"18","key":"4342_CR61","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","volume":"126","author":"R Kridel","year":"2015","unstructured":"Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, et al. Cell of origin of transformed follicular lymphoma. Blood. 2015;126(18):2118\u201327.","journal-title":"Blood"},{"issue":"3","key":"4342_CR62","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","volume":"80","author":"T Yano","year":"1992","unstructured":"Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood. 1992;80(3):758\u201367.","journal-title":"Blood"},{"issue":"14","key":"4342_CR63","first-page":"3894","volume":"63","author":"LA Smit","year":"2003","unstructured":"Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin\u2019s lymphomas of germinal-center phenotype. Cancer Res. 2003;63(14):3894\u20138.","journal-title":"Cancer Res"},{"issue":"9","key":"4342_CR64","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830\u20137.","journal-title":"Nat Genet"},{"key":"4342_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens7010028","volume":"7","author":"SD Dojcinov","year":"2018","unstructured":"Dojcinov SD, Fend F, Quintanilla-Martinez L. EBV-positive lymphoproliferations of B- T- and NK-cell derivation in nonimmunocompromised hosts. Pathogens. 2018;7:28.","journal-title":"Pathogens"},{"key":"4342_CR66","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/PAS.0000000000001499","volume":"44","author":"S Miyagi","year":"2020","unstructured":"Miyagi S, Ishikawa E, Nakamura M, Shimada K, Yamamura T, Furukawa K, et al. Reappraisal of primary Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma of the gastrointestinal tract: comparative analysis among immunosuppressed and nonimmunosuppressed stage I and II-IV patients. Am J Surg Pathol. 2020;44:1173\u201383.","journal-title":"Am J Surg Pathol"},{"key":"4342_CR67","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1002\/cam4.1595","volume":"7","author":"E Ishikawa","year":"2018","unstructured":"Ishikawa E, Tanaka T, Shimada K, Kohno K, Satou A, Eladl AE, et al. A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era. Cancer Med. 2018;7:3510\u201320.","journal-title":"Cancer Med"},{"key":"4342_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101172","volume":"65","author":"H Witte","year":"2024","unstructured":"Witte H, K\u00fcnstner A, Gebauer N. Update: the molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas. Blood Rev. 2024;65:101172.","journal-title":"Blood Rev"},{"issue":"1","key":"4342_CR69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1182\/blood-2011-01-330795","volume":"118","author":"I Salaverria","year":"2011","unstructured":"Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, German High-Grade Lymphoma Study Group, Berlin-Frankfurt-M\u00fcnster-NHL trial group. Translocations activating IRF4 identify a subtype of germinal center-derived B cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139\u201347.","journal-title":"Blood"},{"issue":"3","key":"4342_CR70","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/PAS.0b013e31826b9b57","volume":"37","author":"Q Liu","year":"2013","unstructured":"Liu Q, Salaverria I, Pittaluga S, Jegalian AG, Xi L, et al. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 2013;37(3):333\u201343.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4342_CR71","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.17811","volume":"196","author":"RD Morin","year":"2022","unstructured":"Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol. 2022;196(4):814\u201329.","journal-title":"Br J Haematol"},{"key":"4342_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.622648","volume":"11","author":"P Li","year":"2021","unstructured":"Li P, Chai J, Chen Z, Liu Y, Wei J, Liu Y, et al. Genomic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma. Front Oncol. 2021;11:622648.","journal-title":"Front Oncol"},{"issue":"1","key":"4342_CR73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40164-022-00325-7","volume":"11","author":"SS Li","year":"2022","unstructured":"Li SS, Zhai XH, Liu HL, Liu TZ, Cao TY, Chen DM, et al. Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma. Exp Hematol Oncol. 2022;11(1):71.","journal-title":"Exp Hematol Oncol"},{"key":"4342_CR74","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211072839","volume":"13","author":"R Chen","year":"2022","unstructured":"Chen R, Zhou D, Wang L, Zhu L, Ye X. MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022;13:20406207211072839.","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"4342_CR75","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1080\/10428194.2017.1370546","volume":"59","author":"M Frick","year":"2018","unstructured":"Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, et al. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL. Leuk Lymphoma. 2018;59(5):1260\u20133.","journal-title":"Leuk Lymphoma"},{"key":"4342_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.28","volume":"3","author":"W Kraan","year":"2013","unstructured":"Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, et al. High preva lence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.","journal-title":"Blood Cancer J"},{"issue":"5","key":"4342_CR77","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","volume":"107","author":"A Dodero","year":"2022","unstructured":"Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica. 2022;107(5):1153\u201362.","journal-title":"Haematologica"},{"issue":"15","key":"4342_CR78","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"key":"4342_CR79","doi-asserted-by":"crossref","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E,et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759-71.","DOI":"10.1182\/blood.2019003535"},{"issue":"17","key":"4342_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178132","volume":"26","author":"N Maher","year":"2025","unstructured":"Maher N, Maiellaro F, Ghanej J, Rasi S, Moia R, Gaidano G. Unraveling the epigenetic landscape of mature B cell neoplasia: mechanisms, biomarkers, and therapeutic opportunities. Int J Mol Sci. 2025;26(17):8132 (Published 2025 Aug 22).","journal-title":"Int J Mol Sci"},{"key":"4342_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00389-w","volume":"10","author":"TJ Bakhshi","year":"2020","unstructured":"Bakhshi TJ, Georgel PT. Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer J. 2020;10:123.","journal-title":"Blood Cancer J"},{"key":"4342_CR82","doi-asserted-by":"crossref","unstructured":"Larrabeiti-Etxebarria A, Bilbao-Aldaiturriaga N, Arzuaga-Mendez J, Martin-Arruti M, Cozzuto L, Gaafar A, et al. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma. Sci Rep. 2023;13(1):12159.","DOI":"10.1038\/s41598-023-39271-7"},{"key":"4342_CR83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:17\u201329.","journal-title":"Ann Oncol"},{"issue":"6","key":"4342_CR84","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2010-06-288480","volume":"117","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 2011;117(6):1958\u201365.","journal-title":"Blood"},{"issue":"13","key":"4342_CR85","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12957-015-0668-5","volume":"15","author":"S Zhang","year":"2015","unstructured":"Zhang S, Wang L, Yu D, Shen Y, Cheng S, Zhang L, et al. Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution. World J Surg Oncol. 2015;15(13):246.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"4342_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00596-z","volume":"12","author":"AE Rojek","year":"2022","unstructured":"Rojek AE, Smith SM. Evolution of therapy for limited stage diffuse large B-cell lymphoma. Blood Cancer J. 2022;12(2):33.","journal-title":"Blood Cancer J"},{"issue":"10","key":"4342_CR87","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1002\/cam4.3882","volume":"10","author":"M Wang","year":"2021","unstructured":"Wang M, Ma S, Shi W, Zhang Y, Luo S, Hu Y. Surgery shows survival benefit in patients with primary intestinal diffuse large B-cell lymphoma: a population-based study. Cancer Med. 2021;10(10):3474\u201385.","journal-title":"Cancer Med"},{"key":"4342_CR88","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.929898","volume":"27","author":"F Gao","year":"2021","unstructured":"Gao F, Wang ZF, Tian L, Dong F, Wang J, Jing HM, et al. A prognostic model of gastrointestinal diffuse large B cell lymphoma. Med Sci Monit. 2021;27:e.","journal-title":"Med Sci Monit"},{"issue":"4","key":"4342_CR89","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jgh.14452","volume":"34","author":"T Aoki","year":"2019","unstructured":"Aoki T, Yamada A, Takahashi M, Niikura R, Toyama K, Ushiku T, et al. Development and internal validation of a risk scoring system for gastrointestinal events requiring surgery in gastrointestinal lymphoma patients. J Gastroenterol Hepatol. 2019;34(4):693\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"16","key":"4342_CR90","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"16","key":"4342_CR91","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","volume":"141","author":"Y Song","year":"2023","unstructured":"Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, et al. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood. 2023;141(16):1971\u201381.","journal-title":"Blood"},{"issue":"6","key":"4342_CR92","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/ejh.13871","volume":"109","author":"V De Francesco","year":"2022","unstructured":"De Francesco V, Manta R, Marmo R, Marmo C, Rago A, Antonelli G, et al. Efficacy of Helicobater pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: A systematic review. Eur J Haematol. 2022;109(6):643\u20137.","journal-title":"Eur J Haematol"},{"key":"4342_CR93","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/ejh.13080","volume":"101","author":"E Grignano","year":"2018","unstructured":"Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova YM. The role of radiotherapy as salvage and\/or consolidation treatment in relapsed\/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018;101:150\u20139.","journal-title":"Eur J Haematol"},{"key":"4342_CR94","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1182\/bloodadvances.2018023119","volume":"2","author":"S Dutt","year":"2018","unstructured":"Dutt S, Atallah MB, Minamida Y, Filatenkov A, Jensen KP, Iliopoulou BP, et al. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions. Blood Adv. 2018;2:2568\u201380.","journal-title":"Blood Adv"},{"issue":"10","key":"4342_CR95","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/1078-0432.CCR-18-3781","volume":"25","author":"HM McGee","year":"2019","unstructured":"McGee HM, Jiang D, Soto-Pantoja DR, Nevler A, Giaccia AJ, Woodward WA. Targeting the tumor microenvironment in radiation oncology: proceedings from the 2018 ASTRO-AACR Research Workshop. Clin Cancer Res. 2019;25(10):2969\u201374.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4342_CR96","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.19470","volume":"205","author":"CS Lewis","year":"2024","unstructured":"Lewis CS, Joy G, Jensen P, Barraclough A, Franco N, Talaulikar D, et al. Primary gastric diffuse large B-cell lymphoma: a multicentre retrospective study. Br J Haematol. 2024;205(2):534\u201341.","journal-title":"Br J Haematol"},{"issue":"1","key":"4342_CR97","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13148-020-00948-9","volume":"12","author":"MC Zhang","year":"2020","unstructured":"Zhang MC, Fang Y, Wang L, Cheng S, Fu D, He Y, et al. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. Clin Epigenetics. 2020;12(1):160.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"4342_CR98","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","volume":"8","author":"Y Fang","year":"2023","unstructured":"Fang Y, Zhang MC, He Y, Li C, Fang H, Xu PP, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):381.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4342_CR99","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","volume":"5","author":"QD Shen","year":"2018","unstructured":"Shen QD, Zhu HY, Wang L, Fan L, Liang JH, Cao L, et al. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol. 2018;5(6):e261\u20139.","journal-title":"Lancet Haematol"},{"issue":"1","key":"4342_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35697","volume":"131","author":"X Yin","year":"2025","unstructured":"Yin X, He Q, Liu D, Xie L, Wang H, Chen C, et al. Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study. Cancer. 2025;131(1):e35697.","journal-title":"Cancer"},{"issue":"10","key":"4342_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008895","volume":"12","author":"Z Li","year":"2024","unstructured":"Li Z, Jiang W, Zhou H, Cen H, Zhang M, Lv F, et al. Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-na\u00efve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial. J Immunother Cancer. 2024;12(10):e008895.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4342_CR102","first-page":"CD013365","volume":"9","author":"M Ernst","year":"2021","unstructured":"Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021;9(9):CD013365.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4342_CR103","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","volume":"43","author":"C Qu","year":"2020","unstructured":"Qu C, Ping N, Kang L, Liu H, Qin S, Wu Q, et al. Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden. J Immunother. 2020;43(1):32\u20137.","journal-title":"J Immunother"},{"issue":"15","key":"4342_CR104","doi-asserted-by":"publisher","first-page":"1481080","DOI":"10.3389\/fimmu.2024.1481080","volume":"2","author":"J Ruan","year":"2024","unstructured":"Ruan J, Zhou D, Zhang Y, Zhao D, Wei C, Hu K, et al. Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed\/refractory diffuse large B-cell lymphoma. Front Immunol. 2024;2(15):1481080.","journal-title":"Front Immunol"},{"issue":"17","key":"4342_CR105","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","volume":"7","author":"NL Bartlett","year":"2023","unstructured":"Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7(17):4926\u201335.","journal-title":"Blood Adv"},{"issue":"25","key":"4342_CR106","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood.2023020779","volume":"144","author":"A Dabrowska-Iwanicka","year":"2024","unstructured":"Dabrowska-Iwanicka A, Nowakowski GS. DLBCL: who is high risk and how should treatment be optimized? Blood. 2024;144(25):2573\u201382.","journal-title":"Blood"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04342-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04342-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04342-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:23:08Z","timestamp":1787455388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04342-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":106,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4342"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04342-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest related to the content of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review and does not contain any studies with human participants or animals performed by any of the authors. Therefore, approval by an Institutional Review Board or Ethics Committee was not required. Informed consent: No human participants were involved in this work; informed consent was not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The informed consent form has been exempted. This study was performed in accordance with the Declaration of Helsinki and approved by the Medical Ethics Committee of Renmin Hospital of Wuhan University (WDRY2024-K219).","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}